PMID- 25597314
OWN - NLM
STAT- MEDLINE
DCOM- 20150910
LR  - 20201226
IS  - 1040-8401 (Print)
IS  - 1040-8401 (Linking)
VI  - 34
IP  - 6
DP  - 2014
TI  - Dendritic cell cross talk with innate and innate-like effector cells in antitumor 
      immunity: implications for DC vaccination.
PG  - 517-36
AB  - Dendritic cells (DCs) are key players in the induction of immune responses. 
      Adoptive transfer of autologous mature DCs loaded with tumor-associated antigens 
      is a promising therapy for the treatment of immunogenic tumors. For a long time, 
      its therapeutic activity was thought to depend solely on the induction of 
      tumor-specific CD8+ and CD4+ T cell responses. More recently, DCs were shown to 
      bidirectionally interact with innate and innate-like immune cells, including 
      natural killer (NK), invariant natural killer T (iNKT), and gammadelta T cells. These 
      effector cells can amplify responses induced by DCs via several mechanisms, 
      including induction of DC maturation and conventional T cell priming. In 
      addition, NK, iNKT, and gammadelta T cells possess cytolytic activity and can act 
      directly on tumor cells. Therapeutic strategies targeting these innate and 
      innate-like immune cells hence hold potential to improve current DC vaccination 
      protocols.
FAU - van Beek, Jasper J P
AU  - van Beek JJ
AD  - Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, 
      Radboud University Medical Center, Nijmegen, Netherlands.
FAU - Wimmers, Florian
AU  - Wimmers F
AD  - Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, 
      Radboud University Medical Center, Nijmegen, Netherlands.
FAU - Hato, Stanleyson V
AU  - Hato SV
AD  - Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, 
      Radboud University Medical Center, Nijmegen, Netherlands.
FAU - de Vries, I Jolanda M
AU  - de Vries IJ
AD  - Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, 
      Radboud University Medical Center, Nijmegen, Netherlands; Cancer Center 
      Karolinska, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, 
      Sweden.
FAU - Skold, Annette E
AU  - Skold AE
AD  - Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, 
      Radboud University Medical Center, Nijmegen, Netherlands; Cancer Center 
      Karolinska, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, 
      Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Crit Rev Immunol
JT  - Critical reviews in immunology
JID - 8914819
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Receptors, Antigen, T-Cell, gamma-delta)
SB  - IM
MH  - Adoptive Transfer
MH  - Animals
MH  - Antigens, Neoplasm/genetics/*immunology
MH  - CD4-Positive T-Lymphocytes/cytology/*immunology
MH  - Cancer Vaccines/administration & dosage/genetics/immunology
MH  - Cell Communication/immunology
MH  - Dendritic Cells/cytology/*immunology/transplantation
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunity, Innate
MH  - Killer Cells, Natural/cytology/*immunology
MH  - Mice
MH  - Neoplasms/immunology/pathology/*prevention & control
MH  - Receptors, Antigen, T-Cell, gamma-delta/genetics/immunology
MH  - Signal Transduction
MH  - T-Lymphocytes, Cytotoxic/cytology/*immunology
MH  - Vaccination
EDAT- 2015/01/20 06:00
MHDA- 2015/09/12 06:00
CRDT- 2015/01/20 06:00
PHST- 2015/01/20 06:00 [entrez]
PHST- 2015/01/20 06:00 [pubmed]
PHST- 2015/09/12 06:00 [medline]
AID - 0d73db09061e96ef,54f17a93541b21ea [pii]
AID - 10.1615/critrevimmunol.2014012204 [doi]
PST - ppublish
SO  - Crit Rev Immunol. 2014;34(6):517-36. doi: 10.1615/critrevimmunol.2014012204.